Hsp90 inhibitors in clinical development: AT13387

被引：0
|
作者：
Shapiro, G. [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：16 / 16
页数：1
相关论文
共 50 条
  • [1] ALTERNATE SYNTHESIS OF HSP90 INHIBITOR AT13387
    Liang, Cuirong
    Gu, Lingling
    Yang, Yang
    Chen, Xin
    [J]. SYNTHETIC COMMUNICATIONS, 2014, 44 (16) : 2416 - 2425
  • [2] The HSP90 inhibitor, AT13387, overcomes resistance to crizotinib and second generation ALK inhibitors
    Courtin, A.
    Smyth, A.
    Hearn, K.
    Martins, V.
    Lewis, J.
    Thompson, N.
    Lyons, J.
    Wallis, N.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 168 - 168
  • [3] Total Synthesis of Resorcinol Amide Hsp90 Inhibitor AT13387
    Patel, Bhavesh H.
    Barrett, Anthony G. M.
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 2012, 77 (24): : 11296 - 11301
  • [4] The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor
    Kaur, Jatinder
    Bhardwaj, Atul
    Melancon, Bruce J.
    Blagg, Brian S. J.
    [J]. SYNTHETIC COMMUNICATIONS, 2019, 49 (11) : 1436 - 1443
  • [5] Significance of long term pharmacodynamic actions of the HSP90 inhibitor AT13387
    Curry, Jayne
    Fazal, Lynsey
    Graham, Brent
    Harada, Isobel
    Lyons, John
    Reule, Matthias
    Smyth, Tomoko
    Thompson, Neil
    [J]. CANCER RESEARCH, 2009, 69
  • [6] Activity of the HSP90 Inhibitor, AT13387, in ALK-driven Tumor Models
    Wallis, N.
    Smyth, T.
    Munck, J.
    Rodriguez-Lopez, A.
    Lock, V.
    McMenamin, R.
    Thompson, N.
    Lyons, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : 90 - 90
  • [7] Inhibition of Tumour Growth in a Pancreatic Cancer Xenograft Model by AT13387, an HSP90 Inhibitor
    Shaw, E.
    Thomas, A.
    Ghaneh, P.
    Greenhalf, W.
    Davies, M.
    Costello, E.
    Gibbs, F.
    Lyons, J.
    Neoptolemos, J. P.
    Sibson, D. R.
    [J]. PANCREAS, 2011, 40 (08) : 1353 - 1353
  • [8] The HSP90 inhibitor, AT13387, is effective against multiple mechanisms of kinase inhibitor resistance
    Rodriguez-Lopez, Ana
    Smyth, Tomoko
    McMenamin, Rachel
    Lyons, John
    Thompson, Neil
    Lock, Victoria
    Taverna, Pietro
    Corringham, Robert
    Wallis, Nicola
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [9] Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program
    Kang, Min H.
    Reynolds, C. Patrick
    Houghton, Peter J.
    Alexander, Denise
    Morton, Christopher L.
    Kolb, E. Anders
    Gorlick, Richard
    Keir, Stephen T.
    Carol, Hernan
    Lock, Richard
    Maris, John M.
    Wozniak, Amy
    Smith, Malcolm A.
    [J]. PEDIATRIC BLOOD & CANCER, 2012, 59 (01) : 185 - 188
  • [10] AT13387, an HSP90 inhibitor, is effective in both vemurafenib-sensitive and -resistant melanoma models
    Rodriguez-Lopez, Ana M.
    Smyth, Tomoko
    Curry, Jayne
    Graham, Brent
    McMenamin, Rachel
    Lyons, John
    Thompson, Neil
    Wallis, Nicola
    [J]. CANCER RESEARCH, 2012, 72
12345